- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Bioventus präsentiert Wachstumsstrategie und Turnaround-Plan auf Morgan Stanley Konferenz | 1 | Investing.com Deutsch | ||
| 12.08. | Bioventus auf Canaccord-Konferenz: Strategischer Wachstumspfad | 1 | Investing.com Deutsch | ||
| 11.08. | Cantor Fitzgerald reiterates Overweight rating on Bioventus stock | 1 | Investing.com | ||
| 07.08. | Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance | 3 | Seeking Alpha | ||
| 06.08. | Bioventus Non-GAAP EPS of $0.21, revenue of $147.7M | 1 | Seeking Alpha | ||
| 06.08. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.08. | Bioventus enters into a new $400M credit agreement, lowering interest expenses | 2 | Seeking Alpha | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 04.08. | Bioventus, Inc.: Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity | 1 | GlobeNewswire (USA) | ||
| 31.07. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Bioventus erhält FDA-Zulassung für zwei neue Geräte zur Schmerztherapie | 1 | Investing.com Deutsch | ||
| 30.07. | Bioventus receives FDA clearance for two pain management devices | 2 | Investing.com | ||
| 30.07. | Bioventus gets FDA nod for pain management devices | 1 | Seeking Alpha | ||
| 30.07. | Bioventus wins FDA nod for duo of next-gen peripheral nerve stim products | 2 | MassDevice | ||
| 30.07. | Bioventus, Inc.: Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products | 272 | GlobeNewswire (Europe) | DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug... ► Artikel lesen | |
| 29.07. | Bioventus, Inc.: Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 16.07. | Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating | 2 | Insider Monkey | ||
| 07.07. | Cantor Fitzgerald initiates Bioventus stock with Overweight rating on growth potential | 1 | Investing.com | ||
| 04.06. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Bioventus reiterates 2025 guidance with focus on growth and profitability | 1 | Seeking Alpha | ||
| 06.05. | Bioventus Q1 2025 slides: 5% organic growth despite revenue decline, maintains guidance | 2 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,225 | +1,41 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 162,59 | 0,00 % | Praxis Precision Medicines announces proposed public offering | ||
| AVIDITY BIOSCIENCES | 48,780 | -3,39 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,970 | -0,85 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| RECURSION PHARMACEUTICALS | 6,360 | 0,00 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| ADMA BIOLOGICS | 14,560 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| CG ONCOLOGY | 41,850 | -2,72 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,910 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,876 | +2,20 % | Alternative zu BioNTec, Evotec und Co.: BioNxt Solutions überzeugt auf Investorenkonferenz und weckt Übernahmefantasie | Während die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung, die Abnehmspritze... ► Artikel lesen | |
| BIONTECH | 89,90 | -0,06 % | Diese Biotech-Aktie könnte Big Pharma das Fürchten lehren - mit einem oralen Abnehm-Blockbuster und Milliardenpotenzial bei MS! | Anzeige / WerbungWährend die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,990 | 0,00 % | Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 | Conference Call to be Held at 8:00am ET
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,110 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) | SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to... ► Artikel lesen | |
| QUANTUM-SI | 2,535 | 0,00 % | Cathie Wood's ARK buys Genedx, sells Quantum-Si stock | ||
| DAY ONE BIOPHARMACEUTICALS | 7,470 | -3,92 % | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 5,305 | 0,00 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,860 Euro und damit -1,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.